Navigation Links
Clostridium difficile Infection: Strategic Approaches for Better Outcomes
Date:6/15/2009

Complimentary Continuing Education Live Lectures for Healthcare Professionals

VOORHEES, N.J., June 15 /PRNewswire/ -- In recent years, the epidemiology of Clostridium difficile infection (CDI) has been changing. This trend may be the result of antimicrobial use, infection control practices, or other factors. It is critical for healthcare professionals to be aware of the epidemiology of this virulent pathogen and apply evidence-based principles for diagnosis, treatment, and prevention.

To address the need for current education on CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring complimentary continuing education lectures conveniently located at medical institutions across the United States. This activity is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians, pharmacists, and registered nurses.

Faculty for these lectures are leading experts in infectious diseases, gastroenterology, microbiology, epidemiology, and infection control.

Healthcare professionals can visit www.RMEI.com/CDILectures, e-mail CDILectures@RMEI.com, or call toll-free to 1-866-992-9940 to schedule a lecture.

"Robert Michael Educational Institute LLC is committed to providing healthcare professionals with opportunities for quality, innovative, and convenient continuing medical education," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, certified, and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.RMEI.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Clostridium difficile Infection: Current Challenges and Controversies
3. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
7. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. Pharsight Expands Strategic Consulting Services Team
11. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):